Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study

Enrique M. Ocio, MDPhD, Aurore Perrot, Pierre Bories, MD, Jesus F. San-Miguel, MD PhD, Igor W Blau, MD PhD, Lionel Karlin, MD, Joaquin Martinez-Lopez, MD PhD, Wolfram Pönisch, MD, Sara Bringhen, MD, Fabio Ciceri, MD, María-Victoria Mateos, MD PhD, Paula Rodriguez-Otero, Nadia Le Roux, Yvonne Dong, Thomas Fitzmaurice, PhD, Corina Oprea, MD, Philippe Moreau, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136569

Published: 2020

Journal Articles

Phase II Study of Stimulation of Healthy Sibling Donors with Single-Shot Pegfilgrastim - Update (EUDRACT Nr: 2005-004971-39)

Vladan Vucinic, MD, Sabine Leiblein, PhD, Kristina Schakols, MD, Claudia Nehring, MD, Yvonne Remane, PhD, Madlen Jentzsch, MD, Sebastian Schwind, MD, Wolfram Pönisch, MD, Runa Stiegler, MD, Constanze Kliem, MD, Michael Cross, PhD, Dietger Niederwieser, MD

Blood (2018) 132 (Supplement 1): 2064.

https://doi.org/10.1182/blood-2018-99-118531

Published: 2018

Journal Articles

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Heinz Ludwig, MD, Wolfram Pönisch, MD, Stefan Knop, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, MD PhD, Eberhard Gunsilius, MD, Karl Jochen Krenosz, MD, Andreas Petzer, MD, Katja Weisel, MD, Hermann Einsele, MD PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2018) 132 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2018-99-118061

Published: 2018

Journal Articles

Reduction of Immunosuppression after Disease-Specific Donor Cell Chimerism Decrease Can Prevent Hematological Relapse Following Allogeneic Stem Cell Transplantation after Non-Myeloablative (NMA) Conditioning — Results of a Prospective Phase II Study. Eudract #: 2007-002420-15

Vladan Vucinic, Saskia Hell, Madlen Jentzsch, MD, Michael Cross, PhD, Sabine Leiblein, Wolfram Pönisch, MD, Georg-Nikolaus Franke, MD, Gerhard Behre, MD, Thoralf Lange, MD, Sebastian Schwind, MD, Dietger Niederwieser, MD

Blood (2017) 130 (Supplement 1): 3230.

https://doi.org/10.1182/blood.V130.Suppl_1.3230.3230

Published: 2017

Journal Articles

In AML RAS pathway Mutations Confer Worse Outcome in IDH1 and IDH2 Mutated AML Patients Receiving Hematopoietic Stem Cell Transplantation

Stefanie Beinicke, MSc, Juliane Grimm, Madlen Jentzsch, MD, Marius Bill, PhD, Janine Häntschel, MSc, Karoline Goldmann, Julia Schulz, Michael Cross, PhD, Georg-Nikolaus Franke, MD, Vladan Vucinic, Wolfram Pönisch, MD, Gerhard Behre, MD, Dietger Niederwieser, MD, Sebastian Schwind, MD

Blood (2017) 130 (Supplement 1): 2037.

https://doi.org/10.1182/blood.V130.Suppl_1.2037.2037

Published: 2017

Journal Articles

High Expression of the DNMT3A Embedded Pri- Mir -1301 Associates with Improved Outcome in Patients with Acute Myeloid Leukemia

Janine Häntschel, MSc, Madlen Jentzsch, MD, Juliane Grimm, Marius Bill, Stefanie Beinicke, MSc, Laura K. Schmalbrock, MD, Lynn Bonifacio, MD, Luba Schuhmann, Julia Schulz, Karoline Goldmann, Michael Cross, PhD, Georg-Nikolaus Franke, MD, Vladan Vucinic, Wolfram Pönisch, MD, Gerhard Behre, MD, Dietger Niederwieser, MD, Sebastian Schwind, MD

Blood (2017) 130 (Supplement 1): 1203.

https://doi.org/10.1182/blood.V130.Suppl_1.1203.1203

Published: 2017

Journal Articles

Prognostic Impact of Clonal Hematopoiesis in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission

Juliane Grimm, Marius Bill, PhD, Madlen Jentzsch, MD, Stefanie Beinicke, MSc, Janine Häntschel, MSc, Karoline Goldmann, Julia Schulz, Michael Cross, PhD, Wolfram Pönisch, MD, Vladan Vucinic, Gerhard Behre, MD, Thoralf Lange, MD, Georg-Nikolaus Franke, MD, Dietger Niederwieser, MD, Sebastian Schwind, MD

Blood (2017) 130 (Supplement 1): 406.

https://doi.org/10.1182/blood.V130.Suppl_1.406.406

Published: 2017

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Heinz Ludwig, MD, Wolfram Pönisch, MD, Alexander Egle, MD, Stefan Knop, MD, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, Eberhard Gunsilius, Michael A. Fridrik, MD, Andreas Petzer, MD, Katja C. Weisel, Dietger Niederwieser, MD, Axel Hinke, PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2017) 130 (Supplement 1): 1857.

https://doi.org/10.1182/blood.V130.Suppl_1.1857.1857

Published: 2017

Journal Articles

High Pri- Mir-181a-1 and Pri- Mir-181a-2 Expression Associates with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning

Sebastian Schwind, MD, Madlen Jentzsch, MD, Marius Bill, PhD, Karoline Schubert, Laura Schmalbrock, Heike Weidner, Laura Kloss, Taqiuddine Gaber, Lynn Bonifacio, MD, Kathrin Wildenberger, Wolfram Pönisch, MD, Vladan Vucinic, MD, Georg-Nikolaus Franke, MD, Thoralf Lange, MD, Michael Cross, PhD, Gerhard Behre, MD, Dietger Niederwieser, MD

Blood (2014) 124 (21): 732.

https://doi.org/10.1182/blood.V124.21.732.732

Published: 2014

Journal Articles

Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

Blood (2014) 124 (21): 280.

https://doi.org/10.1182/blood.V124.21.280.280

Published: 2014

Journal Articles

Prognostic Implications of Pri-Mir-320a Expression in Acute Myeloid Leukemia Patients

Taqiuddine Gaber, Marius Bill, PhD, Madlen Jentzsch, MD, Karoline Schubert, Heike Weidner, Laura Kloss, Laura Schmalbrock, Bonifacio Lynn, MD, Kathrin Wildenberger, Wolfram Pönisch, MD, Vladan Vucinic, MD, Georg-Nikolaus Franke, MD, Thoralf Lange, MD, Michael Cross, PhD, Gerhard Behre, MD, Dietger Niederwieser, MD, Sebastian Schwind, MD

Blood (2014) 124 (21): 1037.

https://doi.org/10.1182/blood.V124.21.1037.1037

Published: 2014

NARROW

Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study

Phase II Study of Stimulation of Healthy Sibling Donors with Single-Shot Pegfilgrastim - Update (EUDRACT Nr: 2005-004971-39)

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Reduction of Immunosuppression after Disease-Specific Donor Cell Chimerism Decrease Can Prevent Hematological Relapse Following Allogeneic Stem Cell Transplantation after Non-Myeloablative (NMA) Conditioning — Results of a Prospective Phase II Study. Eudract #: 2007-002420-15

In AML RAS pathway Mutations Confer Worse Outcome in IDH1 and IDH2 Mutated AML Patients Receiving Hematopoietic Stem Cell Transplantation

High Expression of the DNMT3A Embedded Pri- Mir -1301 Associates with Improved Outcome in Patients with Acute Myeloid Leukemia

Prognostic Impact of Clonal Hematopoiesis in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

High Pri- Mir-181a-1 and Pri- Mir-181a-2 Expression Associates with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning

Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

Prognostic Implications of Pri-Mir-320a Expression in Acute Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only